Journal of Infectious Diseases & Preventive Medicine
Open Access

Diagnosis and Prevention of Bacterial and Fungal Infections in Children and Adults

Andrea Dalbeni^{* *}Correspondence: Andrea Dalbeni, Department of Infectious Diseases, University of Milan, Milan, Italy, Email:

Author info »

Description

Infectious diseases have been a constant threat to human health, affecting both children and adults. Among the myriad of pathogens, bacterial and fungal infections remain significant contributors to morbidity and mortality. Bacterial infections are prevalent in both children and adults. In children, common bacterial infections include otitis media, streptococcal pharyngitis, and urinary tract infections. These infections often present with non-specific symptoms, making early diagnosis challenging. Pediatricians rely on careful clinical examination and laboratory tests to differentiate between bacterial and viral causes. The judicious use of antibiotics is critical in children to minimize antibiotic resistance and adverse effects. This requires a delicate balance between treating the infection and allowing the child's immune system to fight the bacteria naturally. In contrast, adults tend to develop bacterial infections like pneumonia, urinary tract infections, and skin and soft tissue infections. The management of these infections may require broader spectrum antibiotics and, in some cases, hospitalization. Antibiotic resistance is a growing concern, and healthcare providers must consider antimicrobial stewardship to combat this issue effectively [1].

Fungal infections, on the other hand, often manifest differently in children and adults. In children, superficial fungal infections like ringworm and oral thrush are relatively common. These infections can usually be treated with topical antifungals. However, invasive fungal infections, such as invasive aspergillosis and candidemia, are rare in healthy children but can be lifethreatening. In these cases, antifungal therapy and, occasionally, surgical intervention are necessary. Prevention is a key strategy in managing bacterial and fungal infections. Vaccination plays a crucial role in preventing bacterial infections in both children and adults. For instance, vaccines like the Haemophilus Influenzae Type B (Hib) vaccine and pneumococcal vaccine have significantly reduced the incidence of invasive bacterial infections in children. In adults, vaccines like the influenza and pneumococcal vaccines are recommended to reduce the risk of bacterial pneumonia and sepsis [2].

Treatment for bacterial infections

Antibiotics: Bacterial infections are typically treated with antibiotics. These medications work by targeting and destroying the bacteria causing the infection. The choice of antibiotic depends on the type of bacteria and its susceptibility to specific drugs. Proper antibiotic selection is crucial to avoid overuse, which can lead to antibiotic resistance. Healthcare providers must use antibiotics judiciously and consider factors like the patient's age, allergies, and underlying health conditions [3].

Dose and duration: Completing the full course of antibiotics as prescribed is essential to ensure that all bacteria are eradicated. Premature discontinuation of treatment can lead to the survival of resistant strains, potentially causing a relapse of the infection. Moreover, healthcare providers must consider the appropriate dosage and duration to maximize efficacy while minimizing side effects [4].

Avoiding risk factors: Individuals with weakened immune systems, such as those with HIV/AIDS, cancer, or organ transplants, should take extra precautions to avoid exposure to fungi. This may involve avoiding certain activities or environments, like gardening, where fungal exposure is higher [5].

Infection control measures: In healthcare settings, strict infection control measures, including the use of personal protective equipment and isolation of infected patients, are vital in preventing the nosocomial spread of bacterial infections [6].

Treatment of fungal infections

Antifungal medications: Fungal infections are typically treated with antifungal drugs. The choice of medication depends on the type of fungus and the site of the infection. Common antifungals include fluconazole, amphotericin B, and voriconazole. The duration of treatment varies depending on the severity and type of infection [7].

Topical treatments: Superficial fungal infections, such as athlete's foot or ringworm, can often be treated with over-thecounter or prescription topical antifungal creams or ointments.

Surgical intervention: Invasive fungal infections may require surgical procedures to remove infected tissue or drain abscesses, especially when antifungal therapy alone is insufficient [8].

Environmental control: In healthcare settings, maintaining proper ventilation and infection control measures can help prevent the spread of airborne fungal pathogens. This is especially important in preventing healthcare-associated fungal infections [9].

Antifungal prophylaxis: In some high-risk situations, healthcare providers may consider antifungal prophylaxis to prevent fungal infections. However, this should be carefully evaluated and reserved for cases where the benefits outweigh the risks [10].

Conclusion

This treatment and prevention of bacterial and fungal infections require a comprehensive approach that encompasses both medical interventions and public health strategies. Antibiotics and antifungal medications play a crucial role in treating these infections, but their appropriate use and the prevention of antibiotic resistance are paramount. Additionally, vaccination, hand hygiene, and infection control measures are effective tools in preventing bacterial infections, while maintaining personal hygiene and avoiding risk factors are preventing fungal infections. Public awareness and collaboration between healthcare providers and patients are essential in the ongoing battle against these infectious diseases.

References

1. Ciccarone D. Fentanyl in the US heroin supply: A rapidly changing risk environment. Int J Drug Policy. 2017;46:107-111.

   [Crossref] [Google Scholar] [PubMed]

2. Larney S, Peacock A, Mathers BM, Hickman M, Degenhardt L. A systematic review of injecting-related injury and disease among people who inject drugs. Drug Alcohol Depend. 2017;171:39-49.

   [Crossref] [Google Scholar] [PubMed]

3. Janjua NZ, Islam N, Kuo M, Yu A, Wong S, Butt ZA, et al. Identifying injection drug use and estimating population size of people who inject drugs using healthcare administrative datasets. Int J Drug Policy. 2018;55:31-39.

   [Crossref] [Google Scholar] [PubMed]

4. Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990â??2017: analysis for the Global Burden of Disease Study. Lancet. 2020;395(10219):200-211.

   [Crossref] [Google Scholar] [PubMed]

5. Barocas JA, Gai MJ, Amuchi B, Jawa R, Linas BP. Impact of medications for opioid use disorder among persons hospitalized for drug use-associated skin and soft tissue infections. Drug Alcohol Depend. 2020;215:108207.

   [Crossref] [Google Scholar] [PubMed]

6. Krawczyk N, Eisenberg M, Schneider KE, Richards TM, Lyons BC, Jackson K, et al. Predictors of overdose death among high-risk emergency department patients with substance-related encounters: a data linkage cohort study. Ann Emerg Med. 2020;75(1):1-2.

   [Crossref] [Google Scholar] [PubMed]

7. Cox J, Stone T, Ryan P, Burkle J, Jandarov R, Mendell MJ, et al. Residential bacteria and fungi identified by high-throughput sequencing and childhood respiratory health. Environ Res. 2022;204:112377.

   [Crossref] [Google Scholar] [PubMed]

8. Karvonen AM, Kirjavainen PV, Täubel M, Jayaprakash B, Adams RI, Sordillo JE, et al. Indoor bacterial microbiota and development of asthma by 10.5 years of age. J. Allergy Clin Immunol. 2019;144(5):1402-1410.

   [Crossref] [Google Scholar] [PubMed]

9. Man WH, van Houten MA, Mérelle ME, Vlieger AM, Chu ML, Jansen NJ, et al. Bacterial and viral respiratory tract microbiota and host characteristics in children with lower respiratory tract infections: a matched case-control study. Lancet Respir Med. 2019;7(5):417-426.

   [Crossref] [Google Scholar] [PubMed]

10. Che D, Zhou H, Li T, Wu B. Duration and intensity of fluconazole for prophylaxis in preterm neonates: a meta-analysis of randomized controlled trials. BMC Infect Dis. 2016;16:1-7.

    [Crossref] [Google Scholar] [PubMed]